Story Highlights:
- President Trump unveils landmark deals with Eli Lilly and Novo Nordisk to dramatically lower prices for widely used weight-loss drugs.
- New agreements mean Wegovy, Zepbound, and related treatments could drop to $150 per month for some doses, with expanded coverage for Medicare and Medicaid.
- The announcement aims to make breakthrough obesity medications more affordable for millions, addressing key healthcare and cost concerns.
The Story:
In a high-profile White House event, President Trump announced game-changing agreements with pharmaceutical giants Eli Lilly and Novo Nordisk to slash drug prices for Americans battling obesity. Under the new deals, certain popular GLP-1 treatments such as Wegovy and Zepbound can be accessed for as little as $150–$350 per month for starter doses, a dramatic reduction from past prices above $1,000 monthly. The move expands insurance coverage through Medicare and Medicaid, while a new TrumpRx government platform will allow direct consumer purchases at reduced rates starting in January 2026.
Officials say these price cuts will help millions who pay out-of-pocket for obesity medications and extend lower costs to seniors and low-income patients as well. The move continues Trump’s push for “most favored nation” drug pricing—aligning U.S. costs with those seen overseas. Companies also agreed to three-year tariff exemptions and product guarantees under the deal.
Why It Matters:
Rising prescription costs remain a central concern for American voters, and the dramatic accessibility increases for breakthrough obesity drugs could have major public health impacts. Trump’s deal is credited with forcing industry action during a time of deep healthcare policy debate and historic government shutdown.
Takeaway:
Millions of Americans could save hundreds of dollars monthly thanks to landmark drug price cuts—potentially transforming obesity care nationwide.
Sources Used:
